Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Sublingual Spray for Postoperative Pain
NCT02310581Phase 3Terminated
- Sponsor
- Insys Therapeutics
- Start
- Feb 2015
- Primary completion
- Mar 2015
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of v1003 in postoperative pain (4 arms), sponsored by Insys Therapeutics. Primary endpoint: Numeric Rating Scale Summed Pain Intensity Difference Over 0 to 48 Hours. Started Feb 2015; status: terminated.
02
Drugs
v1003
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02310581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310581.